UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

Traditionally, scientists believed that obesity led to type 2 diabetes by impairing insulin signaling within liver and fat ...

Monogenic forms of early onset severe childhood obesity (ie, presenting before the age of 5 years) can occur in the context ...

“While GLP-1-based therapies have revolutionized patient care for obesity and Type 2 diabetes ... finding that they increased ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, ...

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection ...

The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well to current treatments.

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver ...

A new study has revealed how genetic variations in the SI gene, which affects sucrose digestion, influence dietary ...

The oral presentation “Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves Metabolism in Obese Mice” highlighted new preclinical ... designed for the treatment of obesity. RJVA ...